Showing 631-640 of 9358 results for "".
- Tralokinumab Achieves Primary and Secondary Endpoints in Three pivotal Phase 3 Trials for ADhttps://practicaldermatology.com/news/tralokinumab-achieves-primary-and-secondary-endpoints-in-three-pivotal-phase-3-trials-for-ad/2460440/LEO Pharma A/S, shared results showing that tralokinumab 300mg, administered subcutaneously every two weeks, demonstrated efficacy and safety with or without concomitant use of a topical corticosteroid (TCS) in three Phase 3 trials (ECZTRA 1-3) for the treatment of adults with moderate to severe at…
- BiomX’s BX001 for Acne-Prone Skin Performs Well in Phase 1 Trialhttps://practicaldermatology.com/news/biomxs-bx001-for-acne-prone-skin-performs-well-in-phase-1-1/2460328/BiomX Inc.’s lead candidate BX001 for acne-prone skin met its primary endpoint of safety and tolerability for both doses of BX001 as well as a statistically significant reduction of Cutibacterium acnes (C. acnes) levels for the high dose of BX001 compared to placebo, according to a Phase 1 study. …
- Going for the Gold: Sebacia Microparticles Help Direct Lasers to the Source of Acnehttps://practicaldermatology.com/news/going-for-the-gold-sebacia-microparticles-help-direct-lasers-to-the-source-of-acne/2460199/Sebacia microparticles may be acne’s latest and greatest nemesis. New research presented the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in Chicago shows that the technology helps to safely and effectively clear acne when used with or following pre-treatment with common fi…
- Phase 3 Study: Aclaris Therapeutics’ A-101 45% May Help Thwart Common Wartshttps://practicaldermatology.com/news/phase-3-study-aclaris-therapeutics-a-101-45-may-help-thwart-common-warts/2460198/Aclaris Therapeutics, Inc.’s A-101 45% Topical Solution (A-101 45%), an investigational new drug, for the potential treatment of common warts, performed well in its second Phase 3 clinical trial, THWART-1 (WART-301). A-101 45% met the primary and all secondary efficacy endpoints, achieving clinica…
- Derm Residents Optimize Total Skin Exams Using Bioengineering Principleshttps://practicaldermatology.com/news/derm-residents-optimize-total-skin-exams-using-bioengineering-principles/2460058/Researchers at the Penn State Health Milton S. Hershey Medical Center are using engineering principles to improve the accuracy and efficiency of total body skin exams. There is no standardized method for performing a total body skin exam. Dermatologists may develop their own approach, which can po…
- Dr. Adam Friedman to Serve as Interim Chair of GW's Department of Dermatologyhttps://practicaldermatology.com/news/dr-adam-friedman-to-serve-as-interim-chair-of-gws-department-of-dermatology/2459915/The GW School of Medicine and Health Sciences (SMHS) and the GW Medical Faculty Associates (GW MFA) have selected Adam Friedman, MD, FAAD, professor of dermatology, to serve as the interim chair of the GW Department of Dermatology. He assumed the role on Jan. 31, 2019. Alison Ehrlich, MD, MHS, pro…
- XBiotech Adds Dr. Alice Gottlieb to its Scientific Advisory Boardhttps://practicaldermatology.com/news/xbiotech-adds-dr-alice-gottlieb-to-its-scientific-advisory-board/2457599/Alice Gottlieb, MD, PhD joined XBiotech Inc.'s Scientific Advisory Board (SAB). Dr. Alice Gottlieb is internationally recognized for her expertise and pioneering work in the development of biological therapies to treat skin diseases. Dr. Gottlieb has played key roles in the clinical evaluation of t…
- By the Numbers: The Skin Cancer Foundation's Destination Healthy Skin Initiative Concludeshttps://practicaldermatology.com/news/by-the-numbers-the-skin-cancer-foundations-destination-healthy-skin-initiative-concludes/2457602/With a total of 1,243 free skin cancer screenings to its credit, The Skin Cancer Foundation’s mobile skin cancer education and screening programDestination: Healthy Skinhas concluded its second annual journey around the US. Fifty-three dermatologists volunteered to provide the exams aboard the 3…
- Ortho Dermatologics Names 2018 Aspire Higher Scholarship Recipientshttps://practicaldermatology.com/news/ortho-dermatologics-names-2018-aspire-higher-scholarship-recipients/2457658/Ortho Dermatologics, a division of Bausch Health Companies Inc., has named the 2018 honorees of the Aspire Higher program, which since 2013 has granted more than $450,000 in scholarships to students who have been affected by dermatologic conditions. This year nine students will receive scholarships…
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high risk of recurrence following complete surgical resection show…